AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
Study NCT04403919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Closure: Knee
Description: Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
Study NCT04403919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture closure: Knee
Description: The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
Study NCT04599127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
Study NCT04599127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional physical therapy
Description: The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
Study NCT01000831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adjuvanted Arepanrix
Description: Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
Study NCT01552200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure
Description: Standard Colonoscopy,NaviAid™ G-Eye procedure
Study NCT04599127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
Study NCT03748849 — intervention group
Intervention type: PROCEDURE
Intervention: Physiotherapy
Study NCT03485053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection / MPB-1514
Description: Dilute with 5% Dextrose solution (D5W)
Study NCT04613674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Chemotherapy
Description: camrelizumab+chemotherapy
Study NCT04613674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo+chemotherapy
Description: placebo+chemotherapy
Study NCT04403919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Closure: Hip
Description: 1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson).
Study NCT04403919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture closure: Hip
Description: 1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson).
Study NCT01552200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy
Description: G-Eye procedure, Standard Colonoscopy
Study NCT03102983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI functional
Description: vowels records and MRI session
Study NCT01162551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Methotrexate
Description: Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days.
Study NCT03602443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSVT®BIG Intervention
Description: Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
Study NCT03602443 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LSVT®BIG Intervention
Description: Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
Study NCT03745768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
Study NCT03745768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
Study NCT00893841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine (Seroquel) XR
Description: tablets and caplets, take with liquid before bedtime
Study NCT00893841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine (Seroquel) XR
Description: tablets, take with liquid before bedtime
Study NCT00893841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02019693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Supplied by Novartis as film-coated tablet for oral use.
Study NCT03339908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thalamotomy by gamma Knife radiosurgery
Description: The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
Study NCT03758066 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PlusCare
Description: PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
Study NCT01216761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine tincture
Description: Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
Study NCT01725464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen cannular
Description: Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
Study NCT00809939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alfa hydroxyprogesterone caproate
Description: weekly injection of 250 mg until 34 weeks gestation
Study NCT00809939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural progesterone
Description: previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
Study NCT00809939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alfa hydroxyprogesterone caproate
Description: weekly injection, 250 mg until 34 weeks gestation
Study NCT00809939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: daily vaginal progesterone 200 mg until 34 weeks gestation.
Study NCT02309996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervisor Training Program
Study NCT01777750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS flex pad; Philips Innercool RTx
Description: Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
Study NCT03144518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Affect Intervention
Description: See Previous Description
Study NCT03144518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Control Intervention
Description: See Previous Description
Study NCT03144518 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Description: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Study NCT03144518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Description: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Study NCT03017469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARISE
Description: 1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)
Study NCT04421469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab(JS001)
Description: 1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment.
Study NCT01837940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Galactooligosaccharide (GOS) and rhamnose in a powder formulation
Study NCT01837940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
Study NCT00963625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
Study NCT00963625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh blastocyst transfer
Description: Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
Study NCT03773835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Mmanual IV bolus injection completed in 1 minute.
Study NCT00925977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin Glargine + Insulin Apidra
Description: 12 wees treatment with Insulin Glargine + Insulin Apidra
Study NCT03602443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist Control
Description: Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
Study NCT03602443 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
Study NCT04309318 — intervention group
Intervention type: PROCEDURE
Intervention: Low pneumoperitoneum (10-12 mmHg) pressure range group
Description: Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
Study NCT04309318 — intervention group
Intervention type: PROCEDURE
Intervention: High pneumoperitoneum (13-15 mmHg) pressure range group
Description: Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
Study NCT03776838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl guided by SoC+NOL
Description: Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
Study NCT03776838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Fentanyl guided by SoC
Description: Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
Study NCT02740829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Description: Glucagon will be administered via a nasal dispenser
Study NCT02740829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Placebo
Study NCT00626717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Riboflavin/UVA crosslinking
Description: Removal of epithelium. Riboflavin eye drops. UVA exposure.
Study NCT00626717 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Fluorescein eye drops. Exposure with blue light
Study NCT03687658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.
Study NCT01684436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctal Plug
Description: Punctal plugs inserted into the study eye on Day 1.
Study NCT00940836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resfenol
Description: Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
Study NCT00940836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
Study NCT00940836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Co interventional acetaminophen
Description: All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Study NCT04393350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT04393350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO
Study NCT04393350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04393350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04393350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00893841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole dihydrochloride
Description: tablets and caplets, take with liquid before bedtime
Study NCT00940836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co interventional acetaminophen
Description: All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Study NCT01176214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Description: Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset.
Study NCT00198471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study NCT04814953 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
Study NCT00925977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin NPH + Insulin Apidra: Active Comparator
Description: Insulin NPH + Insulin Apidra: Active Comparator
Study NCT01471145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
Study NCT02574442 — intervention group
Intervention type: DEVICE
Intervention: In Vivo Confocal Microscopy Probe
Description: Participants will have 2 areas on their cervical imaged by the confocal probe.
Study NCT02974465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback Electromyography
Description: protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
Study NCT02974465 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback Electromyography
Description: consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
Study NCT02974465 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional Physical Therapy Treatment
Description: All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...
Study NCT02974465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Treatment
Description: All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...
Study NCT01187784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Cat cognitive-behavioral therapy for anxious youth
Description: Manualized, empirically supported CBT treatment for anxious youth
Study NCT02253537 — intervention group
Intervention type: DEVICE
Intervention: CST001
Study NCT02678936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Application of platelet-rich plasma during surgery
Study NCT01176214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late tracheostomy
Description: Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails